Phase II study of radiochemotherapy with vinblastine in invasive bladder cancer.

Abstract

Concurrent vinablastine-based radiochemotherapy was evaluated in 84 bladder-cancer patients. It was effective in more than half: tumour-specific survival (51% 9-year), local control rate (55% 9-year). The drawback was the impaired function of the bladder (9-year prevalence SOMA G3-4 symptoms: 66%), indicating the need for treatment aimed at reducing chronic morbidity.

• Authors: Borut Kragelj, Lijana Zaletel-Kragelj, Boris Sedmak, Tanja Cufer, Jozica Cervek
• Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (Radiother Oncol) Vol. 75 Issue 1 Pg. 44-7 (Apr 2005) ISSN: 0167-8140 [Print] Ireland
• PMID: 15878100 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article)

Chemical References

• Antineoplastic Agents, Phytogenic
• Vinblastine

Topics

• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Agents, Phytogenic (administration & dosage, therapeutic use)
• Combined Modality Therapy
• Female
• Humans
• Male
• Middle Aged
• Urinary Bladder Neoplasms (drug therapy, radiotherapy)
• Vinblastine (administration & dosage, therapeutic use)